FUJII Chifumi

Academic Assembly School of Medicine and Health Sciences Institute of Medicine

Interdisciplinary Cluster for Cutting Edge Research Institute for Biomedical Sciences 

Assistant Professor 

Field Of Study

  • molecular oncology
  • Experimental pathology
  • Biochemistry


  • 2014
    信州大学学術研究院(医学系)助教 バイオメディカル研究所主担当
  • 2013 - 2014
  • 2007 - 2013
  • 2006 - 2007
  • 2003 - 2006
  • 2001 - 2003

Educational Background

  • 1998 - 2001, 金沢大学大学院, 自然科学研究科, 生命科学専攻
  • 1996 - 1998, 金沢大学大学院, 理学研究科, 化学専攻
  • 1992 - 1996, 金沢大学, 理学部, 化学科


  • Biological Defenses and Regulation of Epithelial Tumor Development by the Gastric Gland Mucus-type Glycan
    FUJII Chifumi, NAKAYAMA Jun
    Shinshu Medical Journal, 70(5), 257-269, Oct. 2022, Refereedリポジトリ電子ジャーナル
  • Glycosylation of MUC6 by α1,4-linked N-acetylglucosamine enhances suppression of pancreatic cancer malignancy.
    Yuki A, Fujii C (co-first author, corresponding author), Yamanoi K, Matoba H, Harumiya S, Kawakubo M, Nakayama J.
    Cancer Sci., 113, 576-586, 2022, Refereed
    Lead, Corresponding
  • MUC6 expression is a preferable prognostic marker for invasive mucinous adenocarcinoma of the lung.
    Yamanoi K, Fujii C (co-first author), Yuzuriha H, Kumazawa M, Shimoda M, Emoto K, Asamura H, Nakayama J.
    Histochem. Cell Biol., 157, 671-684, 2022, Refereed
  • α1,4-linked N-acetylglucosamine suppresses gastric cancer development by inhibiting Mucin-1-mediated signaling.
    Fujii C (corresponding author), Harumiya S, Sato Y, Kawakubo M, Matoba H, Nakayama J.
    Cancer Sci., 113, 3852-3863, 2022, Refereed
    Lead, Corresponding
  • Cholestenone functions as an antibiotic against Helicobacter pylori by inhibiting biosynthesis of the cell wall component CGL
    Kobayashi J, Kawakubo M, Fujii C, Arisaka N, Miyashita M, Sato Y, Komura H, Matoba H, and Nakayama J
    Proc. Natl. Acad. Sci. USA, 118, e2016469118, 2021, Refereed
  • Cecal Tumorigenesis in Aryl Hydrocarbon Receptor-Deficient Mice Depends on Cecum-Specific Mitogen-Activated Protein Kinase Pathway Activation and Inflammation
    Matoba H, Takamoto M*, Fujii C*,Kawakubo M, Kasuga E, Matsumura T, Natori T,Misawa K, Taniguchi S, and Nakayama J (*: Corresponding author)
    Am. J. Pathol., 190, 253-268, 2020, Refereed
  • Analysis of A4gnt knockout mice reveals an essential role for gastric sulfomucins in preventing gastritis cystica profunda
    Kawakubo M, Komura H, Goso Y, Okumura M, Sato Y, Fujii C, Miyashita M, Arisaka N, Harumiya S, Yamanoi K, Yamada S, Kakuta S, Kawashima H, Fukuda MN, Fukuda M, and Nakayama J
    J. Histtochem. & Cytochem., 67, 759-770, 2019, Refereed
  • Annexin A1 expression is correlated with malignant potential of renal cell carcinoma
    Yamanoi M, Yamanoi K1, Fujii C1,2, Fukuda MN, and Nakayama J (1: Contributed equally, 2: Corresponding author)
    Int. J. Urol., 26, 284-290, 2019, Refereed
  • Potential Role of ASC, a Proapoptotic Protein, for Determining the Cisplatin Susceptibility of Lung Cancer Cells
    Sakaizawa T, Matsumura T, Fujii C, Hida S, Toishi M, Shiina T, Yoshida K, Hamanaka K, Ito KI, Taniguchi S
    Tohoku J Exp Med, 244, 133-144, 2018, Refereed
  • Fascin1 suppresses RIG-I-like receptor signaling and interferon-β production by associating with IκB kinase ϵ (IKKϵ) in colon cancer
    Matsumura T, Hida S, Kitazawa M, Fujii C, Kobayashi A, Takeoka M, Taniguchi SI, Miyagawa SI
    J. Bilo. Chem., 293, 6329-6336, 2018, Refereed
  • ASC Induces Apoptosis via Activation of Caspase-9 by Enhancing Gap Junction-Mediated Intercellular Communication.
    Kitazawa M, Hida S, Fujii C, Taniguchi S, Ito K, Matsumura T, Okada N, Sakaizawa T, Kobayashi A, Takeoka M, and Miyagawa S
    PLOS ONE, 12, e0169340, 2017, Refereed
  • Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.
    Ohya A, Yamanoi K, Shimojo H, Fujii C, Nakayama J
    Cancer Sci, 108, 1897-1902, 2017, Refereed
  • Novel role of ASC as a regulator of metastatic phenotype.
    Okada N1, Fujii C1,2, Matsumura T, Kitazawa M, Okuyama R, Taniguchi S, and Hida S. (1: Contributed equally, 2: Corresponding author)
    Cancer Med., 5, 2487-2500, 2016, Refereed
    Lead, Corresponding
  • NFkB2 gene as a novel candidate that epigenetically responds to interval walking training.
    Y. Zhang, S. Hashimoto, C. Fujii, S. Hida, K. Ito, T. Matsumura, T. Sakaizawa, M. Morikawa, S. Masuki, H. Nose, K. Higuchi, K. Nakajima, S. Taniguchi
    Int. J. Sports. Med., 36, 769-775, 2015, Refereed
  • Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.
    Y. Wu, Y. Y. Wang, Y. Nakamoto, Y-Y. Li, T. Baba, S. Kaneko, C. Fujii, and N. Mukaida
    Oncogene, 29, 2228-2237, 2010, Refereed
  • In vivo immunological toxicity in mice of carbon nanotubes with impurities.
    S. Koyama, Y. A. Kim, T. Hayashi, K. Takeuchi, C. Fujii, N. Kuroiwa, H. Koyama, T. Tsukahara, and M. Endo
    Carbon, 47, 1365-1372, 2009, Refereed
  • Blocking TNF-a in mice reduces colorectal carcinogenesis associated with chronic colitis.
    B. K. Popivanova, K. Kitamura, Y. Wu, T. Kondo, T. Kagaya, S. Kaneko, M. Oshima, C. Fujii, and N. Mukaida
    J. Clin. Invest., 118, 560-570, 2008, Refereed
  • Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
    H. C. Zheng, K. Tsuneyama, H. Takahashi, S. Miwa, T, Sugiyama, B. K. Popivanova, C. Fujii, K. Nomoto, N. Mukaida, and Y. Takano
    J. Cancer Res. Clin. Oncol., 134, 481-488, 2008, Refereed
  • Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.
    B. K. Popivanova, Y-Y Li, H. Zheng, K. Omura, C. Fujii, K. Tsuneyama, and N. Mukaida
    Cancer Sci., 98, 321-328, 2007, Refereed
  • Implication of ‘Down syndrome cell adhesion molecule’ in the hippocampal neurogenesis of ischemic monkeys.
    T. Yamashima, B. K. Popivanova, J. Guo, S. Kotani, T. Wakayama, S. Iseki, K. Sawamoto, H. Okano, C. Fujii, N. Mukaida, and A. B. Tonchev
    HIPPOCAMPUS, 16, 924-935, 2006, Refereed
  • Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines.
    Y-Y. Li, B. K. Popivanova, Y. Nagai, H. Ishikura, C. Fujii, and N. Mukaida
    Cancer Res., 66, 6741-6747, 2006, Refereed
  • Esssential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.
    X. Yang, P. Lu, C. Fujii, Y. Nakamoto, J. Gao, S. Kaneko, P. M. Murphy, and N. Mukaida
    Int. J. Cancer, 118, 1869-1876, 2006, Refereed
  • Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages, and neovascularization.
    X. Yang, P. Lu, Y. Ishida, W. A. Kuziel, C. Fujii, and N. Mukaida
    Int. J. Cancer, 118, 335-345, 2006, Refereed
  • Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.
    C. Fujii, Y. Nakamoto, P. Lu, K. Tsuneyama, B. K. Popivanova, S. Kaneko, and N. Mukaida
    Int. J. Cancer, 114, 209-218, 2005, Refereed
  • Spontaneous regression of lung metastasis in the absence of tumor necrosis factor receptor p55.
    Y. Tomita, X. Yang, Y. Ishida, Y. Nemoto-Sasaki, T. Kondo, M. Oda, G. Watanabe, G. N. Chaldakov, C. Fujii, and N. Mukaida
    Int. J. Cancer, 112, 927-933, 2004, Refereed
  • hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitize cervical cancer cells to a low dose of cisplatin.
    M. Nakamura, S. Kyo, T. Kanaya, N. Yatabe, Y. Maida, M. Tanaka, Y. Ishida, C. Fujii, T. Kondo, M. Inoue, and N. Mukaida
    Cancer Gene Ther., 11, 1-7, 2004, Refereed
  • Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas.
    P. Lu, Y. Nakamoto, Y. Nemoto-Sasaki, C. Fujii, H. Wang, M. Hashii, Y. Ohmoto, S. Kaneko, K. Kobayashi, and N. Mukaida
    Am. J. Pathol., 162, 1249-1258, 2003, Refereed
  • Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis.
    K. Kitamura, Y. Nakamoto, M. Akiyama, C. Fujii, T. Kondo, K. Kobayashi, S. Kaneko, and N. Mukaida
    Lab. Invest., 82, 571-583, 2002, Refereed
  • Difference in the way of macrophage recognition of target cells depending on their apoptotic states.
    C. Fujii, A. Shiratsuchi, J. Manaka, S. Yonehara, and Y. Nakanishi
    Cell Death Differ., 8, 1113-1122, 2001, Refereed
  • Essential tyrosine residues in 3-ketosteroid-Δ1-dehydrogenase from Rhodococcus rhodochrous.
    C. Fujii, S. Morii, M. Kadode, S. Sawamoto, M. Iwami, and E. Itagaki
    J. Biochem., 126, 662-667, 1999, Refereed
  • 3-Ketosteroid-Δ1-dehydrogenase of Rhodococcus rhodochrous:Sequencing of the genomic DNA and hyperexpression, purification, and characterization of the recombinant enzyme.
    S. Morii, C. Fujii, T. Miyoshi, M. Iwami, and E. Itagaki
    J. Biochem., 124, 1026-1032, 1998, Refereed

Lectures, oral presentations, etc.

  • αGlcNAc binding to MUC6 enhances suppression of malignant phenotypes of pancreatic cancer cells
    第81回日本癌学会学術総会, Sep. 2022
  • Phenotypic change of pyloric gland mucin represents potentially malignant biomarker for various neoplasm
    第81回日本癌学会学術総会, Sep. 2022
  • Regulation of pancreatic cancer malignancy by αGlcNAc and MUC6
    第31回日本がん転移学会学術集会, Jul. 2022
  • 淡明細胞型腎細胞癌にて悪性度と相関するアネキシンA1は、紡錘細胞型腎細胞癌でも発現した
    第109回日本泌尿器科学会総会, Dec. 2021
  • 胃腺粘液特異的糖鎖αGlcNAcによる胃がん細胞でのMUC1シグナル伝達制御
    第79回日本癌学会学術総会, Oct. 2021
  • MUC6発現は、粘液産生型肺腺癌における予後良好の指標になる
    第79回日本癌学会学術総会, Oct. 2021
  • 胃腺粘液特異的糖鎖αGlcNAc結合新規タンパク質の同定と胃がん細胞における役割
    第28回日本がん転移学会学術集会, Jul. 2021
  • Sirt3のノックダウンはライディッヒ細胞腫由来細胞株MA-10にROS依存性の細胞死を誘導する
    第110回日本病理学会総会, Apr. 2021
  • αGlcNAcとMUC6による膵癌の悪性化制御機能
    第118回日本内科学会講演会, Apr. 2021
  • 胃腺粘液特異的糖鎖αGlcNAcはがん細胞の悪性度を制御する
    第79回日本癌学会学術総会, Oct. 2020
  • 胃腺粘液特異的糖鎖αGlcNAcはがん細胞の悪性度を制御する
    第79回日本癌学会学術総会, Oct. 2020
  • AhRノックアウトマウスの回盲部における腫瘍発生は回盲部に特異的なMAPK経路の活性化と炎症反応に依存する
    第109回日本病理学会総会, Jul. 2020
  • 胃腺粘液特異的糖鎖αGlcNAcによる胃がん細胞の悪性化制御機構
    第29回日本がん転移学会, 2020
  • Gastritis Cystica Profundaの発生抑制における胃スルホムチンの役割の解明(神戸)
    第60回日本組織細胞化学会総会・学術集会および第13回日中組織細胞化学セミナー合同大会(神戸), Sep. 2019
  • Role of gastric gland mucin-specific O-glycan GlcNAc in gastric cancer development
    Chifumi Fujii, Atsuko Yuki, Satoru Harumiya, Kazuhiro Yamanoi, Masatomo Kawakubo, and Jun Nakayama
    ASCB|EMBO meeting 2018(San Diego, USA), Dec. 2018
  • 胃腺粘液特異的糖鎖αGlcNAcはがん細胞の浸潤能を制御する
    第91回日本生化学会大会(京都), Sep. 2018
  • 腎細胞がんにおけるAnnexinA1発現の意義
    山ノ井万里子, 山ノ井一裕, 藤井千文, 福田道子, 中山淳
    第77回日本癌学会学術集会(大阪), Sep. 2018
  • AhRノックアウトマウスの盲腸への腫瘍発生およびそれに対する腸内細菌叢の影響に関する研究
    的場久典, 藤井千文, 谷口俊一郎, 中山淳
    第77回日本癌学会学術集会(大阪), Sep. 2018
  • 胃腺粘液特異的糖鎖であるαGlcNAcによる胃がん細胞の悪性化制御機構
    藤井千文, 中山淳
    第27回日本がん転移学会学術集会(横浜), Jul. 2018
  • AhRノックアウトマウスの盲腸への腫瘍発生および腸内細菌叢の影響に関する研究
    的場久典, 藤井千文, 川久保雅友, 春日恵理子, 高本雅哉, 谷口俊一郎, 中山淳
    第107回日本病理学会総会(札幌), Jun. 2018
  • 腎細胞がんにおけるAnnexinA1発現の意義
    山ノ井万里子, 藤井千文, 山ノ井一裕, 福田道子, 中山淳
    第106回日本泌尿器科学会総会(京都), Apr. 2018
  • 膵癌の発癌過程におけるαGlcNAcの発現意義
    第76回日本癌学会学術総会(横浜), Sep. 2017
  • Novel role of ASC as a regulator of metastatic phenotype
    第41回研究皮膚科学会年次学術大会(仙台), Dec. 2016
  • インフラマソーム構成因子ASCの細胞運動における役割
    第75回日本癌学会学術総会(横浜), Oct. 2016
  • ヒト肺癌の悪性形質獲得におけるASCの役割
    第23回日本がん転移学会学術集会(大阪), Jul. 2015
  • ASCによるがん細胞転移能の制御機構の解析
    第23回日本がん転移学会学術集会(金沢), Jul. 2014
  • The roles of ASC in cancer cell metastasis
    Chifumi Fujii, Tomio Matshmura, Takao Sakaizawa, Shigeaki Hida, and Shun’ichiro Taniguchi.
    15th International Biennial Congress Metastasis Research Society (Germany), Jun. 2014
  • Actin binding protein fascin1 regulates innate immune responses in tumor cells
    日本免疫学会総会・学術集会, Dec. 2013
  • がん細胞でのASC発現低下は細胞運動能を亢進させる
    第72回日本癌学会学術総会, Oct. 2013
  • 細胞間相互作用を介したASC依存的な腫瘍抑制機能
    第72回日本癌学会学術総会, Oct. 2013
  • ASCによるがん細胞運動制御機構の解析
    第22回日本がん転移学会学術集会, Jul. 2013
  • ASCによる生体の恒常性維持と腫瘍増殖制御機構の解析
    第22回日本がん転移学会学術集会, Jul. 2013
  • がん細胞におけるfascin1のRIG-Iシグナル抑制機構の解析
    第22回日本がん転移学会学術集会, Jul. 2013
  • がん細胞におけるASCと細胞運動能の相関性の解析
    第85回日本生化学会大会(福岡), 14 Dec. 2012
  • Imvolvement of fascin in immune responses through inflammasome activation
    Tomio Matsumura, Chifumi Fujii, Shun’ichiro Taniguchi, and Shigeaki Hida
    第41回日本免疫学会総会・学術集会(神戸), 05 Dec. 2012
  • がん細胞におけるASCの新規腫瘍抑制機能
    第71回日本癌学会学術総会(札幌), 19 Sep. 2012
  • Potential involvement of ASC in cancer progression and metastasis.
    Chifumi Fujii, Shigeaki Hida, Masato Kitazawa, Kensuke Ito, and Shun’ichiro Taniguchi.
    14th International Biennial Congress of the Metastasis Research Society (Australia), 02 Sep. 2012
  • 繊維肉腫細胞におけるASCの新規癌抑制機能
    第70回日本癌学会学術総会(名古屋), Oct. 2011
  • マクロファージの抗腫瘍作用におけるApoptosis-associated speck-like protein containing a CARD(ASC)の役割
    第70回日本癌学会学術総会(名古屋), Oct. 2011
  • マクロファージの抗腫瘍作用におけるASCの役割
    第20回日本がん転移学会学術集会・総会(浜松), 30 Jun. 2011

Affiliated academic society

  • 日本生化学会
  • 日本癌学会
  • 日本がん転移学会
  • 日本免疫学会
  • 米国細胞生物学会
  • 日本組織細胞化学会

Research Themes

  • 胃腺粘液特異的糖鎖を指標とした予後不良分化型胃がんの診断・治療法開発
    科学研究費補助金, 基盤研究(C)
    Apr. 2023
  • 胃腺粘液糖鎖αGlcNAcの消失による胃がん悪性化の制御機構
    科学研究費補助金, 基盤研究(C)
    Apr. 2018 - Mar. 2021
  • インフラマソーム構成分子ASCによるがん細胞の転移制御機構の解明
    科学研究費補助金, 基盤研究(C)
    Apr. 2014 - Mar. 2017
  • アダプタータンパク質ASC下流シグナルを標的とした新規大腸がん治療標的分子の同定
    科学研究費補助金, 若手研究(B)
    Apr. 2012 - Mar. 2014
  • 新規素材カーボンナノチューブの毒性および発がん性評価
    科学研究費補助金, 若手研究(B)
    Apr. 2009 - Mar. 2011